INTRODUCTION {#s1}
============

Pneumococcus is an important human pathogen that causes significant morbidity and mortality worldwide ([@B1]). It is one of the most important human pathogens in community-acquired and nosocomial pneumonia, causing an estimated two-thirds of all cases of bacterial pneumonia and resulting in hospitalization and death among older adults ([@B2][@B3][@B6]). One of its main virulence factors is a polysaccharide capsule (serotype), and nearly 100 different serotypes have been identified to date ([@B7], [@B8]).

Pneumococcal conjugate vaccines (PCVs) have been included in the infant vaccination program of more than 100 countries ([@B9]), which has resulted in a significant reduction in disease and circulating vaccine serotypes within those countries. Protection of the unvaccinated adult population through herd immunity is generally observed later than vaccine-induced immunity among the pediatric population ([@B10][@B11][@B12]). Importantly, serotype replacement and the circulation of antimicrobial-resistant pneumococcal lineages expressing non-vaccine serotypes can also occur ([@B13][@B14][@B16]).

In April 2011, the 10-valent PCV (PHiD-CV, Synflorix; GSK) was introduced into the national infant immunization program in a 2 + 1 vaccine schedule, without catch-up vaccination. The vaccine directly targets serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, but the potential cross-protection against vaccine-related serotypes 6A and 19A seems to vary among studies ([@B17][@B18][@B21]). Pneumococcal vaccines had not previously been a part of the routine infant immunization program in Iceland. In this study, we analyzed the impact of PHiD-CV implementation among pneumococci recovered from the lower respiratory tract (LRT) of adult patients. The distribution of pneumococcal serotypes and genetic lineages along with changes in antimicrobial resistance rates were assessed before and after vaccine implementation.

MATERIALS AND METHODS {#s2}
=====================

Study population and bacterial isolates. {#s2.1}
----------------------------------------

All pneumococci isolated from lower respiratory tract (LRT) samples taken from adults ≥18 years of age with suspected pneumonia and submitted to the Department of Clinical Microbiology at Landspitali University Hospital in Iceland between 2009 and 2017 were included in the study. When two or more pneumococcal isolates of the same phenotype (i.e., the same serotype and antimicrobial susceptibility pattern) were identified from the same patient within 30 days, they were considered to be from the same infection, and only the first isolate was included in the subsequent analyses.

The Department of Clinical Microbiology serves as the reference laboratory for the whole country and is the primary microbiology laboratory for the greater Reykjavík capital area. The study was divided into three different periods for the analyses, 3 years prior to vaccination (2009 to 2011, PreVac), 1 to 3 years postvaccination (2012 to 2014, PostVac-I), and 4 to 6 years postvaccination (2015 to 2017, PostVac-II).

The primary catchment area for the Landspitali University Hospital was considered to be within a 100-km driving distance from the hospital, and the population demographic information for this referral region was obtained from Statistics Iceland ([www.statice.is](http://www.statice.is)). The population sizes of the referral region for adults ≥18 years of age (which includes over 70% of Icelandic adults ≥18 years old) were 170,042 (PreVac), 177,490 (PostVac-I), and 186,724 (PostVac-II). The prevalences of the pneumococcal isolates were calculated using the population size of the referral region as the denominator. The population sizes stratified by age group (18 to 64 and ≥65 years old) are shown in Table S1 in the supplemental material.

Serotyping. {#s2.2}
-----------

Serotypes were determined for all available isolates with ImmuLex pool antisera (State Serum Institute, Copenhagen, Denmark) and/or by a multiplex PCR (mPCR) method, which included 78 sets of serogroup/serotype-specific primer pairs. Serotypes of serogroup 6 were identified as previously described ([@B22]). Nonencapsulated Streptococcus pneumoniae (NESp) isolates (i.e., those that were negative for *cpsA* and positive for *lytA*) were tested for the *cpsB* gene, which is essential for encapsulation ([@B23]), using a previously published PCR method ([@B24]).

DNA extraction, whole-genome sequencing, and phylogenetic analysis. {#s2.3}
-------------------------------------------------------------------

DNA extraction and whole-genome sequencing (WGS) were performed as previously described on every other pneumococcal isolate from the years 2009 to 2014 ([@B22]). Multilocus sequence types (STs) and clonal complexes (CCs) were defined in the standard manner. Genome annotation, gene clustering, and sequence alignments were performed using Prokka and Roary. FastTree and ClonalFrameML were used to reconstruct the phylogenetic tree as described in our previous paper ([@B22]). Note that a core genome threshold of 99.6% was calculated for this data set.

Antibiotic susceptibility testing. {#s2.4}
----------------------------------

All isolates were tested for antimicrobial susceptibility to chloramphenicol, erythromycin, tetracycline, trimethoprim-sulfamethoxazole, and clindamycin using disk diffusion tests. Oxacillin disks (1 µg) were used to screen for penicillin resistance. E-tests were used to measure the MIC (bioMérieux, France) of penicillin and ceftriaxone on oxacillin-resistant isolates. Multidrug resistance (MDR) was defined as nonsusceptibility to three or more classes of antimicrobials (regardless of penicillin susceptibility). Susceptibility testing was performed according to the methods and criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) ([@B25]).

Statistical analyses. {#s2.5}
---------------------

A likelihood ratio test ([@B26]) was used to test the null hypothesis of equality when comparing the rate (*r*~1~) of a certain serotype, CC, or ST in a given age group PreVac to the rate (*r*~2~) of the same serotype, CC, or ST in the same age group in PostVac-II (for serotypes) and PostVac-I (for CC/ST). For the CCs and STs, PreVac was compared to PostVac-I (2012 to 2014), as there was no genome sequencing done on pneumococcal isolates after 2014. The two-sided Fisher's exact test was used to calculate the *p* values for antimicrobial resistance by using R version 3.3.2. The level of significance for all tests was ≤0.05. Simpson's diversity index was calculated to assess the change in ST diversity after vaccine implementation ([@B27]).

Ethics. {#s2.6}
-------

This study was approved by The National Bioethics Committee (VSNb2013010015/03.07) and the appropriate authorities at Landspitali University Hospital in Iceland.

RESULTS {#s3}
=======

Demographics. {#s3.1}
-------------

The laboratory received 17,762 samples during the study period ([Fig. 1](#F1){ref-type="fig"}). This yielded 814 pneumococcal isolates, of which 17 isolates were not stored or were nonviable, leaving 797 isolates for further analyses. About 10% of the LRT samples originated from adults residing outside of the primary catchment area. The total number of pneumococcal isolates decreased significantly from 314 (184.7/100,000 adults) PreVac to 230 (123.2/100,000 adults) PostVac-II (*p* = 0.002; [Table 1](#T1){ref-type="table"}). The median age of the patients with confirmed pneumonia was 75.2 years. More than half (430/797, 54.0%) of all isolates obtained were from patients ≥65 years of age, and in this age group, the total number of isolates decreased from 191 (719.8/100,000 adults aged ≥65 years) in the PreVac period to 102 (314.7/100,000 adults aged ≥65 years) in the PostVac-II period (*p* \< 0.001; [Table 2](#T2){ref-type="table"}).

![Annual number of isolates belonging to serotypes targeted by PHiD-CV (vaccine-type \[VT\]), serotypes not targeted by PHiD-CV (non-vaccine-type \[NVT\]), and lower respiratory tract (LRT) samples received by the laboratory. \*, Seven isolates of serotype 19F were detected in the same patient in 2017.](JCM.01766-18-f0001){#F1}

###### 

Serotype distribution for each study year, 2009 to 2017, in adults ≥18 years of age

  Serotype                                             No. of isolates per yr   PreVac isolates (2009--2011)   PostVac-I isolates (2012--2014)   PreVac vs PostVac-I *p* value   PostVac-II isolates (2015--2017)   PreVac vs PostVac-II *p* value                                                                                                                                                                                         
  ---------------------------------------------------- ------------------------ ------------------------------ --------------------------------- ------------------------------- ---------------------------------- -------------------------------- ------- ------- --------------------------------------- ------- --------- ------- --------- --------------------------------------- --------------------------------------- --------- ---------
  3                                                    11                       9                              5                                 9                               3                                  8                                6       7       7                                       25      14.7      20      11.3      0.558                                   20                                      10.7      0.485
  4                                                    0                        0                              1                                 0                               0                                  0                                1       0       0                                       1       0.6       0       0         Nc[^*a*^](#T1F1){ref-type="table-fn"}   1                                       0.5       0.965
  6A                                                   10                       4                              4                                 5                               4                                  0                                1       1       1                                       18      10.6      9       5.1       0.221                                   3                                       1.6       0.016
  6B                                                   9                        10                             2                                 11                              7                                  3                                3       3       1                                       21      12.3      21      11.8      0.927                                   7                                       3.7       0.052
  6C                                                   0                        1                              0                                 1                               1                                  0                                2       7       5                                       1       0.6       2       1.1       0.719                                   14                                      7.5       0.021
  7F                                                   0                        2                              0                                 1                               0                                  0                                2       0       0                                       2       1.2       1       0.6       0.683                                   2                                       1.1       0.951
  8                                                    0                        1                              0                                 0                               0                                  0                                0       0       0                                       1       0.6       0       0         Nc                                      0                                       0         Nc
  9V                                                   3                        4                              2                                 2                               0                                  0                                0       0       0                                       9       5.3       2       1.1       0.136                                   0                                       0         Nc
  9A                                                   1                        0                              1                                 0                               1                                  1                                0       0       0                                       2       1.2       2       1.1       0.977                                   0                                       0         Nc
  9N                                                   0                        1                              0                                 0                               0                                  2                                1       1       2                                       1       0.6       2       1.1       0.136                                   4                                       2.1       Nc
  10                                                   0                        0                              1                                 0                               0                                  0                                0       0       0                                       1       0.6       0       0         Nc                                      0                                       0         Nc
  11A                                                  5                        6                              3                                 2                               6                                  3                                7       4       9                                       14      8.2       11      6.2       0.641                                   20                                      10.7      0.617
  14                                                   8                        7                              0                                 3                               3                                  1                                0       0       1                                       15      8.8       7       3.9       0.229                                   1                                       0.5       0.008
  15A                                                  1                        1                              0                                 1                               3                                  1                                2       2       4                                       2       1.2       5       2.8       0.470                                   8                                       4.3       0.230
  15B/C                                                3                        0                              5                                 3                               5                                  3                                4       6       1                                       8       4.7       11      6.2       0.694                                   11                                      5.9       0.749
  16F                                                  2                        3                              0                                 1                               1                                  0                                0       1       0                                       5       2.9       2       1.1       0.426                                   1                                       0.5       0.231
  17F                                                  0                        0                              1                                 0                               0                                  1                                0       0       0                                       1       0.6       1       0.6       0.984                                   0                                       0         Nc
  18B                                                  0                        0                              1                                 0                               0                                  0                                0       0       0                                       1       0.6       0       0         Nc                                      0                                       0         Nc
  18C                                                  2                        0                              0                                 0                               0                                  0                                0       0       0                                       2       1.2       0       0         Nc                                      0                                       0         Nc
  19F                                                  30                       45                             24                                29                              23                                 15                               1       1       18[^*b*^](#T1F2){ref-type="table-fn"}   99      58.2      67      37.7      0.068                                   20[^*b*^](#T1F2){ref-type="table-fn"}   10.7      \<0.001
  19A                                                  5                        3                              2                                 3                               4                                  6                                4       5       3                                       10      5.9       13      7.3       0.730                                   12                                      6.4       0.891
  20                                                   0                        0                              1                                 0                               0                                  0                                0       0       0                                       1       0.6       0       0         Nc                                      0                                       0         Nc
  21                                                   1                        0                              0                                 1                               1                                  0                                1       1       4                                       1       0.6       2       1.1       0.719                                   6                                       3.2       0.217
  22F                                                  4                        3                              5                                 5                               1                                  3                                5       4       1                                       12      7.1       9       5.1       0.619                                   10                                      5.4       0.670
  23F                                                  8                        11                             7                                 7                               4                                  4                                2       0       0                                       26      15.3      15      8.5       0.219                                   2                                       1.1       0.001
  23A                                                  3                        0                              0                                 1                               1                                  2                                5       2       6                                       3       1.8       4       2.3       0.832                                   13                                      7.0       0.111
  23B                                                  0                        1                              3                                 0                               2                                  3                                5       4       1                                       4       2.4       5       2.8       0.859                                   10                                      5.4       0.337
  24F                                                  0                        0                              0                                 0                               0                                  0                                1       1       0                                       0       0         0       0         Nc                                      2                                       1.1       Nc
  31                                                   0                        1                              0                                 0                               0                                  0                                0       0       0                                       1       0.6       0       0         Nc                                      0                                       0         Nc
  33F                                                  2                        1                              1                                 3                               0                                  0                                1       1       0                                       4       2.4       3       1.7       0.774                                   2                                       1.1       0.536
  34                                                   1                        0                              0                                 0                               0                                  0                                1       0       0                                       1       0.6       0       0         Nc                                      1                                       0.5       0.965
  35F                                                  0                        1                              1                                 3                               3                                  4                                1       3       3                                       2       1.2       10      5.6       0.123                                   7                                       3.7       0.298
  35B                                                  2                        1                              3                                 4                               1                                  2                                3       7       4                                       6       3.5       7       3.9       0.895                                   14                                      7.5       0.289
  Not determined[^*c*^](#T1F3){ref-type="table-fn"}    0                        1                              0                                 0                               1                                  2                                0       0       4                                       1       0.6       3       1.7       0.518                                   4                                       2.1       0.396
  NESp[^*d*^](#T1F4){ref-type="table-fn"}              2                        5                              6                                 4                               7                                  8                                11      13      11                                      13      7.6       19      10.7      0.534                                   35                                      18.7      0.054
  Total                                                113                      122                            79                                99                              82                                 72                               70      74      86                                      314     184.7     253     142.5     0.043                                   230                                     123.2     0.002
  VT[^*e*^](#T1F5){ref-type="table-fn"}                59                       77                             34                                53                              37                                 23                               9       4       20                                      170     100.0     113     63.7      0.013                                   33                                      17.7      \<0.001
  NVT[^*f*^](#T1F6){ref-type="table-fn"}               54                       45                             45                                46                              45                                 49                               61      70      66                                      144     84.7      140     78.9      0.693                                   197                                     105.5     0.184
  All LRT samples                                      2,153                    1,976                          1,676                             1,750                           1,671                              1,620                            2,176   2,384   2,356                                   5,805   3,413.9   5,041   2,840.2   \<0.001                                 6,916                                   3,703.9   0.003
  Percentage of LRT samples positive for pneumococci   5.2                      6.2                            4.7                               5.7                             4.9                                4.4                              3.2     3.1     3.7                                     5.4               5.0                                                       3.3                                               

Nc, not calculated.

Seven isolates of serotype 19F were detected in the same patient in 2017.

Serotypes other than those included in the multiplex PCR panel of the study.

NESp, nonencapsulated S. pneumoniae.

Serotypes detected in the study that are targeted by PHiD-CV (4, 6B, 7F, 9V, 14, 18C, 19F, and 23F).

Serotypes detected in the study that are not targeted by PHiD-CV.

###### 

Serotype distribution within each age group during the PreVac (2009 to 2011), PostVac-I (2012 to 2014), and PostVac-II (2015 to 2017) periods in LRT samples

  Serotype                                            18--64 yrs   ≥65 yrs                                                                                                                                                                   
  --------------------------------------------------- ------------ --------- ----- ------ --------------------------------------- ----- ------ --------- ----- ------- ----- ------- ------- --------------------------------------- ------- ---------
  3                                                   9            6.3       9     6.1    0.963                                   11    7.1    0.851     16    60.3    11    37.7    0.425   9                                       27.8    0.209
  4                                                   1            0.7       0     0      Nc[^*a*^](#T2F1){ref-type="table-fn"}   1     0.6    0.973     0     0       0     0       Nc      0                                       0       Nc
  6A                                                  6            4.2       2     1.3    0.325                                   1     0.6    0.170     12    45.2    7     24.0    0.371   2                                       6.2     0.037
  6B                                                  3            2.1       13    8.8    0.095                                   5     3.2    0.688     18    67.8    8     27.4    0.143   2                                       6.2     0.005
  6C                                                  0            0         2     1.3    Nc                                      7     4.5    Nc        1     3.8     0     0       Nc      7                                       21.6    0.191
  7F                                                  1            0.7       1     0.7    0.988                                   1     0.6    0.973     1     3.8     0     0       Nc      1                                       3.1     0.926
  8                                                   0            0         0     0      Nc                                      0     0      Nc        1     3.8     0     0       Nc      0                                       0       Nc
  9V                                                  2            1.4       2     1.3    0.983                                   0     0      Nc        7     26.4    0     0       Nc      0                                       0       Nc
  9A                                                  0            0         0     0      Nc                                      0     0      Nc        2     7.5     2     6.9     0.950   0                                       0       Nc
  9N                                                  0            0         1     0.7    Nc                                      3     1.9    Nc        1     3.8     1     3.4     0.965   1                                       3.1     0.926
  11A                                                 7            4.9       6     4.0    0.824                                   11    7.1    0.601     7     26.4    5     17.1    0.665   9                                       27.8    0.946
  14                                                  7            4.9       3     2.0    0.379                                   0     0      Nc        8     30.1    4     13.7    0.381   1                                       3.1     0.068
  15A                                                 0            0         4     2.7    Nc                                      6     3.9    Nc        2     7.5     1     3.4     0.662   2                                       6.2     0.895
  15B/C                                               4            2.8       3     2.0    0.781                                   9     5.8    0.400     4     15.1    8     27.4    0.508   2                                       6.2     0.482
  16F                                                 0            0         0     0      Nc                                      1     0.6    Nc        5     18.8    2     6.9     0.401   0                                       0       Nc
  17F                                                 1            0.7       1     0.7    0.988                                   0     0      Nc        0     0       0     0       Nc      0                                       0       Nc
  18B                                                 0            0         0     0      Nc                                      0     0      Nc        1     3.8     0     0       Nc      0                                       0       Nc
  18C                                                 1            0.7       0     0      Nc                                      0     0      Nc        1     3.8     0     0       Nc      0                                       0       Nc
  19F                                                 39           27.2      22    14.8   0.126                                   7     4.5    0.001     60    226.1   45    154.3   0.199   13[^*b*^](#T2F2){ref-type="table-fn"}   40.1    \<0.001
  19A                                                 5            3.5       6     4.0    0.973                                   7     4.5    0.765     5     18.8    7     24.0    0.784   5                                       15.4    0.835
  20                                                  0            0         0     0      Nc                                      0     0      Nc        1     3.8     0     0       Nc      0                                       0       Nc
  21                                                  0            0         2     1.3    Nc                                      4     2.6    Nc        1     3.8     0     0       Nc      2                                       6.2     0.786
  22F                                                 8            5.6       7     4.7    0.525                                   5     3.2    0.524     4     15.1    2     6.9     0.536   5                                       15.4    0.982
  23F                                                 14           9.8       6     4.0    0.264                                   0     0      Nc        12    45.2    9     30.9    0.566   2                                       6.2     0.037
  23A                                                 2            1.4       3     2.0    0.983                                   6     3.9    0.375     1     3.8     1     3.4     0.965   7                                       21.6    0.191
  23B                                                 1            0.7       3     2.0    0.715                                   4     2.6    0.388     3     11.3    2     6.9     0.715   6                                       18.5    0.638
  24F                                                 0            0         0     0      Nc                                      1     0.6    Nc        0     0       0     0       Nc      1                                       3.1     Nc
  31                                                  1            0.7       0     0      Nc                                      0     0      Nc        0     0       0     0       Nc      0                                       0       Nc
  33F                                                 0            0         3     2.0    Nc                                      2     1.3    Nc        4     15.1    0     0       Nc      0                                       0       Nc
  34                                                  0            0         0     0      Nc                                      1     0.6    Nc        1     3.8     0     0       Nc      0                                       0       Nc
  35F                                                 1            2.1       5     3.4    0.272                                   2     1.3    0.731     1     3.8     5     17.1    0.293   5                                       15.4    0.332
  35B                                                 3            2.1       2     1.3    0.749                                   7     4.5    0.441     3     11.3    5     17.1    0.703   7                                       21.6    0.522
  Not determined[^*c*^](#T2F3){ref-type="table-fn"}   1            2.1       3     2.0    0.514                                   1     0.6    0.973     1     3.8     0     0       NC      3                                       9.0     0.585
  NESp[^*d*^](#T2F4){ref-type="table-fn"}             6            4.2       7     4.7    0.886                                   25    16.2   0.028     7     26.4    12    41.1    0.532   10                                      30.9    0.833
  Total                                               123          85.7      116   78.2   0.641                                   128   82.9   0.864     191   719.8   137   469.8   0.011   102                                     314.7   \<0.001
  VT[^*e*^](#T2F5){ref-type="table-fn"}               67           46.7      47    31.7   0.176                                   14    9.1    \<0.001   107   403.2   65    222.9   0.022   19                                      61.7    \<0.001
  NVT[^*f*^](#T2F6){ref-type="table-fn"}              56           39.0      69    46.5   0.519                                   114   73.9   0.008     84    316.6   72    246.9   0.201   83                                      253.0   0.367

Nc, not calculated.

Seven isolates of serotype 19F were detected in the same patient in 2017.

Serotypes other than those included in the multiplex PCR panel of the study.

NESp, nonencapsulated S. pneumoniae.

Serotypes detected in the study that are targeted by PHiD-CV (4, 6B, 7F, 9V, 14, 18C, 19F, and 23F).

Serotypes detected in the study that are not targeted by PHiD-CV.

Serotyping. {#s3.2}
-----------

Among all 797 pneumococcal isolates, 789 (99.0%) were successfully serotyped, but 8 isolates were of serotypes other than those included in the mPCR scheme and were not characterized further. Overall, 31 serotypes were detected, 28 in the PreVac period and 24 each in the PostVac-I and PostVac-II periods. Overall, isolates of serotypes 4, 6B, 7F, 9V, 14, 18C, 19F, and 23F, which are targeted by PHiD-CV (vaccine type \[VT\]), decreased significantly between the PreVac and PostVac-II periods (*p* \< 0.001; [Table 1](#T1){ref-type="table"}). VT serotypes 1 and 5 were not detected in the study. The prevalence of isolates with serotypes not targeted by PHiD-CV (non-vaccine type \[NVT\]) did not change significantly (*p* = 0.184; [Table 1](#T1){ref-type="table"}). VTs were most prevalent in 2010 (77/122; 63.1%) and least prevalent in 2016 (4/74; 5.4%) ([Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

Overall, among vaccine-related serotypes 6A and 19A, the frequency of serotype 19A did not change during the study period (PreVac, *n* = 10; PostVac-I, *n* = 13; and PostVac-II, *n* = 12), but serotype 6A decreased significantly from the PreVac to PostVac-II period (*n* = 18 versus *n* = 3, respectively; *p* = 0.016; [Table 1](#T1){ref-type="table"}). Notably, serotype 6C increased significantly from PreVac to PostVac-II (*n* = 1 versus *n* = 14, respectively; *p* = 0.021; [Table 1](#T1){ref-type="table"}).

Analyses by age group revealed that while the prevalence of VT pneumococci decreased significantly in both age groups, the prevalence of NVT and NESp isolates increased significantly in adults aged 18 to 64 years (*p* = 0.008 and 0.028, respectively). There was a nonsignificant decrease in the incidence of serotype 3 in the ≥65-year age group (from 60.3/100,000 adults in the PreVac period to 27.8/100,000 adults in the PostVac-II period). There was no significant change in the overall prevalence of NVT or NESp isolates in the ≥65-year age group ([Table 2](#T2){ref-type="table"}).

CC/MLST. {#s3.3}
--------

Between 2009 and 2014, 567 pneumococcal isolates were recovered and 275 (48.5%) of these isolates were sequenced, among which 41 different CCs (31 CCs PreVac and 32 CCs PostVac-I) and 73 STs (56 STs PreVac and 47 STs PostVac-I) were detected. There was no difference in the ST diversity between the two periods (Simpson's diversity indexes of the STs were 0.97 PreVac and 0.96 PostVac-I).

A phylogenetic tree was created with concatenated sequences of 1,130 full-length coding loci found in 99.6% of the pneumococcal genomes. The tree was annotated with CC designations and serotypes ([Fig. 2](#F2){ref-type="fig"}).

![Midrooted phylogenetic tree, created from 1,221 full-length coding loci found in 99.6% of 275 genomes from LRT samples, annotated with CC designations. Serotypes (inner circle) are presented using the same colors as the appropriate CC where possible. Study periods (outer circle) are also presented.](JCM.01766-18-f0002){#F2}

The most prevalent CC in both study periods was CC236/271/320^19F^, which comprised 31.2% (49/157 \[28.8/100,000 adults\]) of the PreVac pneumococci, but this CC decreased to 24.6% (29/118 \[16.3/100,000 adults\]) in the PostVac-I period (*p* = 0.010) ([Fig. 2](#F2){ref-type="fig"}; see also Table S3 in the supplemental material). Minimal and insignificant changes in the prevalence of other CCs were observed, although the prevalence of CC433^22F^ decreased in the PostVac-I period (*p* = 0.042) ([Fig. 2](#F2){ref-type="fig"}; Table S3).

Antimicrobial resistance. {#s3.4}
-------------------------

Approximately one-third of pneumococci were resistant to penicillin and/or erythromycin in all three study periods, and there was no significant change in those resistance rates over time ([Table 3](#T3){ref-type="table"}; see also Table S2 in the supplemental material). MDR pneumococci decreased from 34.4% in the PreVac period to 23.9% in the PostVac-II period (*p* = 0.010; [Table 4](#T4){ref-type="table"}). Prior to PHiD-CV implementation, 87.9% (102/116) of isolates that were penicillin nonsusceptible were also MDR, but this was reduced to 72.9% (51/70; *p* = 0.016) in the PostVac-II period ([Table 5](#T5){ref-type="table"}). This reduction was related mainly to the decrease in MDR serotype 19F pneumococci.

###### 

PNSP serotypes during the PreVac (2009 to 2011) and PostVac-II (2015 to 2017) periods

  PNSP serotype                                       PreVac isolates   PostVac-II isolates   *p* value                                      
  --------------------------------------------------- ----------------- --------------------- --------------------------------------- ------ ---------------------------------------
  6A                                                  0                 0                     1                                       1.4    0.458
  6B                                                  8                 6.9                   5                                       7.1    1.000
  6C                                                  0                 0                     5                                       7.1    0.007
  9V                                                  4                 3.4                   0                                       0      Nc[^*a*^](#T3F1){ref-type="table-fn"}
  9A                                                  1                 0.9                   0                                       0      1.000
  11A                                                 0                 0                     1                                       1.4    0.376
  14                                                  3                 2.6                   1                                       1.4    1.000
  15A                                                 0                 0                     5                                       7.1    0.007
  15B/C                                               0                 0                     1                                       1.4    0.376
  19F                                                 91                78.4                  20[^*b*^](#T3F2){ref-type="table-fn"}   28.6   \<0.001
  19A                                                 2                 1.7                   0                                       0      Nc
  22F                                                 0                 0                     2                                       2.9    0.209
  23F                                                 1                 0.9                   0                                       0      1.000
  23A                                                 0                 0                     3                                       4.3    0.094
  23B                                                 0                 0                     3                                       4.3    0.094
  35B                                                 0                 0                     6                                       8.6    0.003
  Not determined[^*c*^](#T3F3){ref-type="table-fn"}   1                 0.9                   0                                       0      1.000
  NESp[^*d*^](#T3F4){ref-type="table-fn"}             5                 4.3                   17                                      24.3   \<0.001
  Total PNSP                                          116               100                   70                                      100    0.121
  Total pneumococcal isolates                         314               36.9                  230                                     30.4   0.002

Nc, not calculated.

Seven isolates of serotype 19F were detected in the same patient in 2017.

Serotypes other than those included in the multiplex PCR panel of the study.

NESp, nonencapsulated S. pneumoniae.

###### 

MDR pneumococcal serotypes during the PreVac (2009 to 2011) and PostVac-II (2015 to 2017) periods

  MDR serotype                                        PreVac isolates   PostVac-II isolates   *p* value                                      
  --------------------------------------------------- ----------------- --------------------- --------------------------------------- ------ ---------
  6A                                                  1                 0.9                   0                                       0      1.000
  6B                                                  9                 8.3                   5                                       9.1    1.000
  6C                                                  1                 0.9                   9                                       16.4   \<0.001
  14                                                  2                 1.9                   1                                       1.8    1.000
  15A                                                 1                 0.9                   5                                       9.1    0.017
  15B/C                                               0                 0                     1                                       1.8    0.337
  19F                                                 87                80.6                  20[^*a*^](#T4F1){ref-type="table-fn"}   36.4   \<0.001
  23F                                                 1                 0.9                   0                                       0      1.000
  23A                                                 0                 0                     1                                       1.8    0.337
  35B                                                 0                 0                     1                                       1.8    0.337
  Not determined[^*b*^](#T4F2){ref-type="table-fn"}   1                 0.9                   0                                       0      1.000
  NESp[^*c*^](#T4F3){ref-type="table-fn"}             5                 4.6                   12                                      21.8   \<0.001
  Total MDR serotypes                                 108               100                   55                                      100    0.010
  Total pneumococcal isolates                         314               34.4                  230                                     23.9   0.002

Seven isolates of serotype 19F were detected in the same patient in 2017.

Serotypes other than those included in the multiplex PCR panel of the study.

NESp, nonencapsulated S. pneumoniae.

###### 

PNSP serotypes that were also MDR PreVaC (2009 to 2011) and PostVac-II (2015 to 2017)

  PNSP/MDR serotype                                   PreVac isolates   PostVac-II isolates   *p* value                                      
  --------------------------------------------------- ----------------- --------------------- --------------------------------------- ------ ---------
  6B                                                  8                 6.9                   5                                       7.1    1.000
  6C                                                  0                 0                     5                                       7.1    0.007
  14                                                  2                 1.7                   1                                       1.4    1.000
  15A                                                 0                 0                     5                                       7.1    0.007
  15B/C                                               0                 0                     1                                       1.4    0.376
  19F                                                 87                75.0                  20[^*a*^](#T5F1){ref-type="table-fn"}   28.6   \<0.001
  23A                                                 0                 0                     1                                       1.4    0.376
  35B                                                 0                 0                     1                                       1.4    0.376
  Not determined[^*b*^](#T5F2){ref-type="table-fn"}   1                 0.9                   0                                       0      1.000
  NESp[^*c*^](#T5F3){ref-type="table-fn"}             4                 3.4                   12                                      17.1   0.002
  Total PNSP/MDR                                      102               87.9                  51                                      72.9   0.016
  Total PNSP                                          116               100                   70                                      100    0.121

Seven isolates of serotype 19F were detected in the same patient in 2017.

Serotypes other than those included in the multiplex PCR panel of the study.

NESp, nonencapsulated S. pneumoniae.

Serotype 19F isolates were the most prevalent penicillin-nonsusceptible pneumococci (PNSP) and MDR pneumococci in all three study periods. A total of 78.4% of PNSP and 80.6% of MDR pneumococci recovered in the PreVac period were serotype 19F, but this decreased to 28.6% and 36.4%, respectively, in the PostVac-II period (*p* \< 0.001 for both; [Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Nearly all (91.8%) of the sequenced PNSP serotype 19F isolates were members of the internationally distributed MDR lineage CC236/271/320^19F^ (Taiwan^19F^-14; [Table 3](#T3){ref-type="table"} and [Fig. 2](#F2){ref-type="fig"}; see also Table S3 in the supplemental material).

There were three serotypes, 6C, 15A, and 35B, that were not associated with penicillin resistance in the PreVac period, but each serotype described 7 to 9% of the PNSP by the PostVac-II period ([Table 3](#T3){ref-type="table"}). Similarly, there were changes among the MDR pneumococci of all three of these serotypes; in particular, there were significant increases in MDR serotype 6C and 15A pneumococci (16.4% \[*n* = 9\] and 9.1% \[*n* = 5\] PostVac-II, respectively) ([Tables 3](#T3){ref-type="table"}[to](#T4){ref-type="table"}[5](#T5){ref-type="table"}). Among all PNSP isolates, NESp isolates increased from 4.3% to 24.3% from the PreVac period to the PostVac-II period (*p* \< 0.001), of which 17.1% were also MDR (*p* = 0.002; [Tables 3](#T3){ref-type="table"} to [5](#T5){ref-type="table"}). The overall number of isolates of serotypes 6C, 15A, and 35B and that of the NESp isolates was relatively low, and only every other isolate from 2009 to 2014 was chosen for genome sequencing. Therefore, only a few of each of these pneumococci were selected for genome sequencing, and it is difficult to draw any major conclusions about the genetic lineages associated with these PNSP or MDR pneumococci, except to say that the characterized STs corresponded to widely distributed genetic lineages such as ST344^NT^ and ST315^6B^ ([Fig. 2](#F2){ref-type="fig"}; Table S3).

DISCUSSION {#s4}
==========

The results of this study demonstrated an indirect (herd) effect of PHiD-CV among adults by decreasing the overall number of LRT samples and the proportion of those samples that were positive for pneumococci and by causing a reduction in the proportion of pneumococci that were of vaccine serotypes. The vaccine-induced herd effect leading to a reduction in the incidence of pneumococcal serotypes in unvaccinated children and adults has been widely studied for invasive pneumococcal disease (IPD) ([@B10], [@B28][@B29][@B31]), but few studies have documented a herd effect on vaccine serotypes in adults with pneumonia ([@B11], [@B32]).

High vaccine coverage (\>70 to 80%) leads to extensive herd protection in a population ([@B33]), which becomes evident in the adult population within a few years following vaccine implementation ([@B10], [@B12]). At the beginning of the PostVac-II period, over 97% of Icelandic children \<5 years of age were fully vaccinated ([@B34]). We assessed the differences in the prevalences of pneumococcal serotypes between two postimplementation periods by comparing the PreVac period (2009 to 2011) to both the PostVac-I (2012 to 2014) and PostVac-II (2015 to 2017) periods. The relatively rapid establishment of herd protection and the decline of VTs in adults ([@B29], [@B30], [@B33]) could partly be explained by the high vaccine uptake in Iceland, a country where vaccines are generally well accepted ([@B35]). However, serotype replacement of NVTs has been observed where PCVs have been implemented ([@B36][@B37][@B38]), and this was also the case in our study, although serotype replacement was significant only in adults aged 18 to 64 years.

The penicillin-nonsusceptible and multidrug-resistant serotype 19F isolates were all members of the globally distributed CC236/271/320^19F^ lineage. Serotype 19F was the most prevalent PNSP/MDR serotype in all study periods, although it decreased significantly in the PostVac-II period. The prevalence of PNSP/MDR serotype 19F was unusually high in 2017 compared to that in the two previous years, but this was partly because one 77-year-old immunodeficient patient contributed 7 of the 18 isolates detected that year. However, fluctuations in the prevalence of serotype 19F are also known to occur following PCV introduction, and this will need to be monitored in Iceland going forward ([@B11], [@B38]). Adult infections are frequently a reflection of nasopharyngeal carriage among young children ([@B31]), but interestingly, serotype 19F was not detected in 2017 among healthy Icelandic children or in Icelandic children with acute otitis media ([@B22]). Therefore, it is possible that older children and/or older adults can serve as a reservoir for serotype 19F, and this maintains serotype 19F in the unvaccinated population after vaccine introduction. Serotypes 1 and 5 were not detected in this study. These serotypes are rare in Iceland. Serotype 1 was last detected in 2012, serotype 5 was last detected in 1996, and both serotypes were recovered from patients with IPD (S. J. Quirk, G. Haraldsson, M. Á. Hjálmarssdóttir, H. Erlendsdóttir, and K. G. Kristinsson, unpublished data).

Among vaccine-related serotypes, the prevalence of serotype 6A decreased significantly in the second PostVac period even though it is not a direct target of the vaccine, and other countries that have implemented PHiD-CV have also described similar results ([@B18], [@B20]). Furthermore, in our previous study, the prevalence of serotype 6A decreased in Icelandic children 1 to \<4 years of age with acute otitis media ([@B22]). The possible cross-protection against serotype 19A through the serotype 19F conjugate has been widely debated ([@B17][@B18][@B21]); however, the Icelandic adult population did not appear to benefit from the childhood vaccinations against serotype 19A, since the incidence of serotype 19A did not change between the study periods. Before vaccine implementation in Iceland, serotype 19A was more commonly found in IPD and nasopharyngeal carriage than in non-IPD (acute otitis media and pneumonia), and serotype 19F was predominant in non-IPD ([@B22], [@B39]).

Serotypes 6C and 15A have been reported as upcoming PNSP and MDR serotypes following PCV introduction ([@B13], [@B40], [@B41]), but among adults in Iceland, these serotypes were detected only in low numbers in the PostVac periods of the study. Our group has also detected MDR isolates of serotype 6C that were members of CC315^6B/6C^ and ST386^6C^ (a double locus variant of PMEN Poland^6B^-20) among children ([@B22], [@B39]), but it remains to be seen whether CC315^6C^ will replace CC236/271/320^19F^ as a major MDR lineage in Iceland.

Notably, the prevalence of NESp isolates increased significantly, and they were the most frequently detected pneumococci in the PostVac-II period in adults aged 18 to 64 years. The opposite was seen in the United States, where NESp isolates decreased in adults between the ages of 50 and 64 years, with a parallel increase among adults ≥65 years of age ([@B32]).

Increased vaccine pressure caused by PCVs might open an environmental niche that NESp is adept to employ. This could explain the increased prevalence of NESp isolates in the PostVac-II period, or the increase might simply be a natural trend that reflects longer-term variation ([@B42], [@B43]). Our data support the need for continued surveillance of pneumococci in Iceland. It should be noted that some serotypes were found only in low numbers; therefore, the statistical power for detecting a difference in the frequency between the PreVac and PostVac periods among these serotypes was low.

Following the financial crisis in Iceland in 2008, physicians were advised to reduce test samples at the Landspitali University Hospital, and as a result, fewer LRT samples were received from 2010 to 2014. In the following years, when the effect of the crisis subsided, the number of LRT samples gradually increased again, but at the same time, the number of pneumococcal isolates continued to decrease. This decrease was particularly evident among patients aged ≥65 years, and PCV introduction into childhood immunization programs has been shown to be very beneficial for older adults ([@B11], [@B33]).

Most of the LRT samples in this study were sputum samples; thus, some pneumococcal isolates may represent colonization, although colonization among adults is rare ([@B44]), and sputum samples should have been collected only from patients with suspected pneumonia and not healthy adults. Therefore, using the number of positive pneumococcal isolates as a proxy for pneumococcal pneumonia could be considered a weakness. In general, the financial crisis mentioned above was the only known factor influencing sampling. Vaccine uptake area, guidelines, the health care system, and microbiological methods remained the same during the study period.

The herd effect became evident in our study 3 to 4 years after PHiD-CV implementation and was associated with significant changes in both the serotype distribution and the number of pneumococcal isolates cultured from the lower respiratory tract samples of adults. Pneumococcus was the most frequent pathogen recovered from adults with pneumonia in Iceland prior to vaccination ([@B45]); hence, the protection of older adults through pneumococcal vaccination and herd immunity is of the utmost importance.
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